| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5954473 | Chest | 2014 | 7 Pages |
Abstract
Ivacaftor was clinically effective in patients with CF who carry the G551D mutation and have severe pulmonary disease. The reductions in treatment requirements were clinically and statistically significant and have not been described in less severe populations.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Peter J. MBBCh, Barry J. MD, Arjun MBChB, Stephen MBChB, Nicholas J. MD, Nicholas J. MBChB, Nadia T. MD, Thomas MD, Susan MBBS, Imogen MBBS, Cedric MBBCh, Andrew M. MD, Alex R. PhD,